Christos Vaklavas
( out of 185 reviews )

Christos Vaklavas, MD

Languages spoken: English, Modern Greek, German

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital North

2K, Gynecology and Mammography
1950 Circle of Hope
Salt Lake City , UT 84112
801-213-4269
Get Directions

Farmington Health Center

165 N. University Ave.
Farmington , UT 84025
801-213-3200
Get Directions

  • Dr. Christos Vaklavas is a Professor of Medicine in the Division of Oncology, Department of Internal Medicine at the University of Utah and Huntsman Cancer Institute. Throughout his career, Dr. Vaklavas has developed a broad research program in breast cancer that spans the full spectrum from laboratory investigations to clinical trials.

    His laboratory research focuses on mechanisms of mRNA translation and the discovery of compounds that disrupt oncogenic translation. This work has been supported by a Young Investigator Award from the American Society of Clinical Oncology (ASCO) and a Career Catalyst Award in Basic and Translational Research from Susan G. Komen.

    As the Breast Cancer Translational Science Lead at Huntsman Cancer Institute, Dr. Vaklavas directs a multidisciplinary research program that integrates laboratory and clinical studies. In this role, he serves as a liaison between laboratory-based scientists and clinical researchers to help translate innovative discoveries into meaningful clinical applications.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 185 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    FARMINGTON HEALTH CENTER

    Very aware of all of the new changes and progress in my diagnosis.

    HUNTSMAN CANCER CENTER

    I really like Dr. Vaklavas, he did run about 1/2 hour late for our appointment.

    HUNTSMAN CANCER CENTER

    He was very focused on me and never had to refer to the computer about what my issue was, he knew. He figured out why I was having pain within minutes after I had been dismissed by other doctors. Would highly recommend. He makes you feel heard and that your comfort and well being is important.

    FARMINGTON HEALTH CENTER

    Very good explaining everything!

    FARMINGTON HEALTH CENTER

    Dr. Vaklavas is the best of the best!

    HUNTSMAN CANCER CENTER

    He is a kind, caring, and wonderful doctor

    FARMINGTON HEALTH CENTER

    Very caring and concerned with how my treatments are going. Very concerned with getting me cured and finishing out all my treatments.

    HUNTSMAN CANCER CENTER

    So caring and personable. Great doctor explained everything in layperson terms.

    FARMINGTON HEALTH CENTER

    Unlike other doctors, I truly look forward to seeing him. He seems totally invested in giving you the best care available. Ask him a question and he will put on a seminar to answer it. Express a concern, and he will address it. He listens. He cares.

  • Dr. Christos Vaklavas is a Professor of Medicine in the Division of Oncology, Department of Internal Medicine at the University of Utah and Huntsman Cancer Institute. Throughout his career, Dr. Vaklavas has developed a broad research program in breast cancer that spans the full spectrum from laboratory investigations to clinical trials.

    His laboratory research focuses on mechanisms of mRNA translation and the discovery of compounds that disrupt oncogenic translation. This work has been supported by a Young Investigator Award from the American Society of Clinical Oncology (ASCO) and a Career Catalyst Award in Basic and Translational Research from Susan G. Komen.

    As the Breast Cancer Translational Science Lead at Huntsman Cancer Institute, Dr. Vaklavas directs a multidisciplinary research program that integrates laboratory and clinical studies. In this role, he serves as a liaison between laboratory-based scientists and clinical researchers to help translate innovative discoveries into meaningful clinical applications.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Selected Publications

    Journal Article

    1. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD (2009). Molecular basis of statin-associated myopathy. Atherosclerosis, 202(1), 18-28. (Read full publication)
    2. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD (2010). Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf, 33(3), 171-87. (Read full publication)
    3. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R (2012). Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer, 118(5), 1422-8. (Read full publication)
    4. Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R (2011). Phase 1 clinical trials in 83 patients with pancreatic cancer: The M.D. Anderson Cancer Center experience. Cancer, 117(1), 77-85. (Read full publication)
    5. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R (2013). Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology, 60(127), 1611-23. (Read full publication)
    6. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R (2009). Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab, 94(11), 4423-32. (Read full publication)
    7. Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V (2019). TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol, 37(9), 714-722. (Read full publication)
    8. Chae YK, Hong F, Vaklavas C*, Cheng HC, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. (2020). A Phase II Study of AZD4547 in Patients with Tumors harboring Aberrations in the FGFR Pathway: Results from the NCI-MATCH Trial (EAY131) Sub-protocol W. J Clin Oncol, 38(21), 2407-2417.
    9. Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A (2007). 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res, 31(5), 691-4. (Read full publication)
    10. Rugo HS, et al, (I-SPY2 Investigators) (2016). Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med, 375(1), 23-34.
    11. Park JW, et al, (I-SPY2 Investigators) (2016). Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med, 375(1), 11-22.
    12. Turner NC, et al, (PALOMA3 Study Group) (2015). Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med, 373(3), 209-19.
    13. Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011). Common cardiovascular medications in cancer therapeutics. Pharmacol Ther, 130(2), 177-90. (Read full publication)
    14. Vaklavas C, Grizzle WE, Choi H, Meng Z, Zinn KR, Shrestha K, Blume SW (2016). IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells. Tumour Biol, 37(10), 13247-13264. (Read full publication)
    15. Morris GJ, Dawood S, Cortes J, Ward JH, Vaklavas C, Forero A, Ward S, Toppmeyer D (2015). Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat? Semin Oncol, 42(4), e67-79. (Read full publication)
    16. Yadav BS, Bansal A, Sharma SC, Javid SH, Anderson BO, Vaklavas C, Forero A, Ravi V, Patel S, Boudadi K, Chugh R, Morris GJ (2013). A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer. Semin Oncol, 40(2), 135-44. (Read full publication)
    17. Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ (2009). Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience. J Pediatr Hematol Oncol, 31(11), 803-11. (Read full publication)
    18. Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF, Translational Breast Cancer Research Consortium (TBCRC). (2015). Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin Cancer Res, 21(12), 2771-9. (Read full publication)
    19. Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC, Translational Breast Cancer Research Consortium (TBCRC). (2015). TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res, 21(12), 2722-9. (Read full publication)
    20. Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE, Corey SJ (2010). Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res, 16(4), 1149-58. (Read full publication)
    21. Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, Pusztai L, Petricoin E, Blenman KRM, Balko JM, I-SPY2 Trial Team (2021). Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clin Cancer Res, 27(19), 5299-5306.
    22. Vaklavas C, Zinn KR, Samuel SL, Meng Z, Grizzle WE, Choi H, Blume SW (2018). Translational control of the undifferentiated phenotype in ER'positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition. Oncol Rep, 39(6), 2482-2498. (Read full publication)
    23. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM (2010). Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist, 15(2), 130-41. (Read full publication)
    24. Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, LoBuglio AF, Forero-Torres A (2013). Phase I study of a modified regimen of ¿¿Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. Cancer Biother Radiopharm, 28(5), 370-9. (Read full publication)
    25. Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A on behalf of the Translational Breast Cancer Research Consortium (2020). TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole with or without bevacizumab in post-menopausal women with newly diagnosed stage II/III hormone receptor positive and HER2 negative breast cancer. Breast Cancer Res, 22(1:22).
    26. Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES. (2021). An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. Breast Cancer Res, 23(1:30).
    27. Vaklavas C, Forero A (2014). Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). BioDrugs, 28(3), 253-63. (Read full publication)
    28. Christakis C, Vaklavas C, Kontos N, Chatzidimitriou C, Tzelepi K, Karanikas M, Christakis E (2004). Pelvic reconstruction of the retroperitoneum after abdominoperineal resection of the rectum using full-thickness skin grafts. Tech Coloproctol, 8 Suppl 1, s85-8. (Read full publication)
    29. Vaklavas C, Forero-Torres A (2011). How do I treat "triple-negative" disease. Curr Treat Options Oncol, 12(4), 369-88. (Read full publication)
    30. Vaklavas C, Meng Z, Choi H, Grizzle WE, Zinn KR, Blume SW (2015). Small molecule inhibitors of IRES-mediated translation. Cancer Biol Ther, 16(10), 1471-85. (Read full publication)
    31. Vaklavas C, Sotelo-Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM (2010). Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J, 7, 256. (Read full publication)
    32. Vaklavas C, Ross JR, Nabell LM, Forero A, Heslin MJ, Wood TE (2012). By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes. J Natl Compr Canc Netw, 10(1), 7-13. (Read full publication)
    33. Coletta AM, Playdon MC, Baron KG, Wei M, Kelley K, Vaklavas C, Beck A, Buys SS, Chipman J, Ulrich CM, Walker D, White S, Oza S, Zingg RW, Hansen PA (2021). The association between time-of-day of habitual exercise training and changes in relevant cancer health outcomes among cancer survivors. PLoS One, 16(10:e0258135).
    34. Vaklavas C, Blume SW, Grizzle WE (2020). Hallmarks and Determinants of Oncogenic Translation Revealed by Ribosome Profiling in Models of Breast Cancer. Transl Oncol, 13(2), 452-470.
    35. Vaklavas C, Steciuk MR, Ren Y, Baird MF, Mikhail FM, Foran JM (2011). A case of acute promyelocytic leukemia without RARα rearrangement and apparently normal cytogenetics. Clin Lymphoma Myeloma Leuk, 11(6), 521-4. (Read full publication)
    36. Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ (2017). Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget, 8(9), 16052-16074. (Read full publication)
    37. Vaklavas C, Blume SW, Grizzle WE (2017). Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development. Front Oncol, 7, 158. (Read full publication)
    38. Vaklavas C, Forero-Torres A (2012). Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol, 3(4), 209-25. (Read full publication)
    39. Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE (2016). Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res, 4(5), 390-9. (Read full publication)
    40. Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A, Translational Breast Cancer Research Consortium (TBCRC (2020). TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast cancer research, 22(1), 22. (Read full publication)
    41. Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty K (2020). Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. Journal of clinical oncology, 38(21), 2407-2417. (Read full publication)

    Book Chapter

    1. Vaklavas C, LoBuglio AF, Saleh M, Yelin M, Forero A (2013). CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE). In Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications; Cancer Drug Discovery and Development series (pp. 211-20). Springer.
    2. Forero A, Vaklavas C, LoBuglio AF (2013). Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies. In Antibody- Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications; Cancer Drug Discovery and Development series (pp. 161-75). Springer.

    Editorial

    1. Vaklavas C, Chatzizisis YS (2011). The changing perspective of cardiology in cancer care. Expert Rev Cardiovasc Ther, 9(1), 1-3. (Read full publication)
    2. Welm BE, Vaklavas C, Welm AL. (2021). Toward improved models of human cancer. APL Bioengineering, 5(1).

    Letter

    1. Chatzizisis YS, Vaklavas C, Giannoglou GD (2008). Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy? [Letter to the editor]. Am J Cardiol, 101(7), 1071. (Read full publication)

    Other

    1. Welm BE, Vaklavas C, Welm A (2021). Erratum: "Toward improved models of human cancer" [APL Bioeng. 5, 010901 (2021)]. APL bioengineering, 5(2), 029901. (Read full publication)

  • News & Podcasts

    Huntsman Cancer Institute News